Tysabri Resubmission: Early Safety Test For New Commissioner

The potential market re-entry for the multiple sclerosis therapy Tysabri (natalizumab) is likely to be one of the most high-profile safety issues facing the FDA under new leadership over the next six months

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet